Abstract:
Methods, systems, and apparatus for fabricating a circuit board. The method includes fabricating, using an additive manufacturing device, a trace layer, a sacrificial layer, a rail layer and a lid. The method includes placing the sacrificial layer on the trace layer such that the raised traces protrude through corresponding openings of the sacrificial layer. The method includes depositing a conductive material on top of the sacrificial layer and the plurality of traces. The method includes removing the sacrificial layer from the trace layer and placing the rail layer on the trace layer such that the raised traces align with the corresponding openings of the rail layer. The method includes connecting one or more electrical components and melting a sealing sheet on top of the rail layer and the electrical components to reinforce connections and to provide protection. The method includes placing the lid on top of the sealing sheet.
Abstract:
Apparatuses and methods for harvesting ambient energy involve repeated circuit reconfiguration. An apparatus includes a primary charge storage device, a first secondary charge storage device, a second secondary charge storage device, and switching circuitry. The switching circuitry is configured to cyclically alter connection of the first and second secondary charge storage devices between a series state and a parallel state. First and second moveable electrically conductive elements may include electrically conductive liquid droplets of materials such as water or mercury. At least one of the primary storage device, the first secondary charge storage device, or the second secondary charge storage device includes a capacitance that varies in response to receipt of ambient energy. Concurrently altering relative capacitance and circuit configuration results in exponential growth of harvested energy.
Abstract:
Enabling quick feature delivery is essential for product success and is therefore a goal of software architecture design. But how may we determine if and to what extent an architecture is “good enough” to support feature addition and modification, or determine if a refactoring effort is successful in that features may be added more easily? The applications may use Feature Space and Feature Dependency, derived from a software project's revision history that capture the dependency relations among the features of a system in a feature dependency structure matrix (FDSM), using features as first-class design elements. The applications may also use a Feature Decoupling Level (FDL) metric that may be used to measure the level of independence among features.
Abstract:
The present invention provides compounds as bacterial topoisomerase inhibitors with antibacterial activity. The present invention also provides pharmaceutical compositions comprising at least one of the compounds and methods of using the compounds and pharmaceutical compositions as antibacterial agents for treating infectious diseases,
Abstract:
Methods are provided of treating cardiac hypertrophy in a mammalian subject comprising administering to the subject an anti-hypertrophic effective amount of an ion channel TR-PV1 inhibitor. The methods include treatment of a symptom of cardiac hypertrophy in the subject comprises cardiac remodeling, cardiac fibrosis, apoptosis, hypertension, or heart failure.
Abstract:
The present invention is a biosensor apparatus that includes a substrate, a source on one side of the substrate, a drain spaced from the source, a conducting channel between the source and the drain, an insulator region, and receptors on a gate region for receiving target material. The receptors are contacted for changing current flow between the source and the drain. The source and the drain are relatively wide compared to length between the source and the drain through the conducting channel.
Abstract:
The present invention provides compounds as bacterial topoisomerase inhibitors with antibacterial activity. The present invention also provides pharmaceutical compositions comprising at least one of the compounds and methods of using the compounds and pharmaceutical compositions as antibacterial agents for treating infectious diseases.
Abstract:
The disclosure herein provides cardiac monitoring and diagnostic system, methods, and devices. A cardiac diagnostic system for detecting potential indicators of cardiac disease comprises: a cardiac monitoring device comprising at least one electrode configured to detect an analog electrical cardiac signal of a user; a cardiac signal filter configured to convert the analog electrical cardiac signal to digital electrocardiogram data; an atypical cardiac sequence detector configured to detect atypical cardiac patterns in the electrocardiogram data that are potentially indicative of cardiac disease; and a notification transmitter configured to generate an alert when a detected atypical cardiac pattern is determined to be indicative of cardiac disease.
Abstract:
The systems, methods, and devices described herein generally relate to achieving accurate and robust motion correction by detecting and accounting for false movements in motion correction systems used in conjunction with medical imaging and/or therapeutic systems. In other words, in some embodiments of the systems, methods, and devices described herein can be configured to detect false movements for motion correction during a medical imaging scan and/or therapeutic procedure, and thereby ensure that such false movements are not accounted for in the motion correction process. Upon detection of false movements, the imaging or therapeutic system can be configured to transiently suppress and/or subsequently repeat acquisitions.
Abstract:
Compounds of formula II are described: wherein D, n, Ra, Rb, and Rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.